AU764091B2 - Humanized monoclonal antibodies that protect against shiga toxin induced disease - Google Patents

Humanized monoclonal antibodies that protect against shiga toxin induced disease Download PDF

Info

Publication number
AU764091B2
AU764091B2 AU20902/99A AU2090299A AU764091B2 AU 764091 B2 AU764091 B2 AU 764091B2 AU 20902/99 A AU20902/99 A AU 20902/99A AU 2090299 A AU2090299 A AU 2090299A AU 764091 B2 AU764091 B2 AU 764091B2
Authority
AU
Australia
Prior art keywords
shiga toxin
seq
antibody
monoclonal antibody
humanized monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU20902/99A
Other languages
English (en)
Other versions
AU2090299A (en
Inventor
Angela Melton-Celsa
Alison D. O'brien
Clare K. Schmitt
Jeffrey R. Stinson
Hing Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunol Molecular Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Sunol Molecular Corp
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunol Molecular Corp, Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Sunol Molecular Corp
Publication of AU2090299A publication Critical patent/AU2090299A/en
Assigned to SUNOL MOLECULAR CORPORATION, HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE reassignment SUNOL MOLECULAR CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: MELTON-CELSA, ANGELA, O'BRIEN, ALISON D., SCHMITT, CLARE K., STINSON, JEFFREY L., WONG, HING
Application granted granted Critical
Publication of AU764091B2 publication Critical patent/AU764091B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU20902/99A 1997-12-23 1998-12-22 Humanized monoclonal antibodies that protect against shiga toxin induced disease Expired AU764091B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6863597P 1997-12-23 1997-12-23
US60/068635 1997-12-23
US09/215,163 US20030170248A1 (en) 1997-12-23 1998-12-18 Humanized monoclonal antibodies that protect against shiga toxin induced disease
US09/215163 1998-12-18
PCT/US1998/027267 WO1999032645A1 (en) 1997-12-23 1998-12-22 Humanized monoclonal antibodies that protect against shiga toxin induced disease

Publications (2)

Publication Number Publication Date
AU2090299A AU2090299A (en) 1999-07-12
AU764091B2 true AU764091B2 (en) 2003-08-07

Family

ID=26749187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20902/99A Expired AU764091B2 (en) 1997-12-23 1998-12-22 Humanized monoclonal antibodies that protect against shiga toxin induced disease

Country Status (11)

Country Link
US (6) US20030170248A1 (enExample)
EP (1) EP1042492B1 (enExample)
JP (1) JP4450505B2 (enExample)
AT (1) ATE449856T1 (enExample)
AU (1) AU764091B2 (enExample)
CA (1) CA2316411C (enExample)
DE (1) DE69841331D1 (enExample)
DK (1) DK1042492T3 (enExample)
ES (1) ES2339618T3 (enExample)
PT (1) PT1042492E (enExample)
WO (1) WO1999032645A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
RU2217166C2 (ru) 1998-05-20 2003-11-27 Тейдзин Лимитед Гуманизированные антитела, которые распознают веротоксин ii, и продуцирующая их линия клеток
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
WO2002070751A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
US6875433B2 (en) * 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
CA2434668A1 (en) 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
CN100441689C (zh) * 2006-01-20 2008-12-10 中国人民解放军第三军医大学 抗ehec o157志贺样毒素ⅱa亚单位单克隆抗体5f3轻、重链可变区基因及应用
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
AU2007254950A1 (en) * 2006-05-31 2007-12-13 Thallion Pharmaceuticals Incorporated Methods, compositions, and kits for treating Shiga toxin associated conditions
EP2172481B1 (en) * 2008-10-06 2014-10-29 Novoplant GmbH Proteolytically stable antibody formats
ES2614803T3 (es) * 2009-01-23 2017-06-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Métodos y composiciones basadas en proteína tipo 2 de la toxina Shiga
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) * 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5747272A (en) * 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) * 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US7910096B2 (en) * 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
US7807184B2 (en) * 2003-07-21 2010-10-05 Interuet International B.V. Hybrid Shiga-like toxin
WO2005075647A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
EP1991565B1 (en) * 2006-02-16 2015-01-21 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Shiga toxoid chimeric proteins
EP2420246A1 (en) * 2006-04-20 2012-02-22 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods and compositions based on shiga toxin type 1 protein
US20090258010A1 (en) * 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.A. CLELAND ET AL. PROTEIN ENGINEERING, PRINCIPLES AND PRACTICES, P 398-434 *

Also Published As

Publication number Publication date
DK1042492T3 (da) 2010-01-18
ES2339618T3 (es) 2010-05-21
CA2316411C (en) 2009-02-17
US20070160607A1 (en) 2007-07-12
JP2003521219A (ja) 2003-07-15
EP1042492A1 (en) 2000-10-11
US20070003560A1 (en) 2007-01-04
US20100166753A1 (en) 2010-07-01
US20140135481A1 (en) 2014-05-15
CA2316411A1 (en) 1999-07-01
ATE449856T1 (de) 2009-12-15
EP1042492B1 (en) 2009-11-25
WO1999032645A1 (en) 1999-07-01
US20030170248A1 (en) 2003-09-11
PT1042492E (pt) 2010-01-08
JP4450505B2 (ja) 2010-04-14
AU2090299A (en) 1999-07-12
DE69841331D1 (de) 2010-01-07
US20100189715A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
US20100189715A1 (en) Humanized monoclonal antibodies that protect against shiga toxin induced disease
US11447543B2 (en) Antibodies to S. aureus surface determinants
Tremblay et al. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2
ES2363689T3 (es) Anticuerpos monoclonales y quiméricos, opsónicos y protectores, específicos para el ácido lipoteicoico de bacterías gram positivas.
Davies et al. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model
CN104203976A (zh) 艰难梭状芽孢杆菌毒素的人源抗体
AU2018202199A1 (en) Clostridium difficile antibodies
Henrique et al. Therapeutic antibodies against Shiga toxins: trends and perspectives
AU2010200341A1 (en) Wall Teichoic Acid as a Target for Anti-Staphylococcal Therapies and Vaccines
AU2013251165A1 (en) Cross-reactive Staphylococcus aureus antibody
CA2560759A1 (en) Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
JP2010013454A (ja) グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体
Ahmadi et al. Anti-flagellin IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound murine models in a non-type-specific mode
CN119241697B (zh) 抗金黄色葡萄球菌铁离子调节表面决定簇b蛋白的单克隆抗体及应用
Barekzi et al. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model
EP2570433A1 (en) Neutralizing human antibodies to anthrax toxin generated by recall technology
WO2014160098A2 (en) Bordetella specific human recombinant antibodies and uses thereof
Motley The Role of Anti-Capsular Antibodies in Protection Against Carbapenem-Resistant Klebsiella Pneumoniae
CN120943954A (zh) 抗金黄色葡萄球菌IsdB抗体的制备及其应用
Harmsen et al. Serum immunoglobulin or albumin
RU2630663C9 (ru) Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
Almdni Recombinant antibodies against Clostridium difficile toxin A
Sheoran et al. A Single VHH-Based Toxin-Neutralizing
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SUNOL MOLECULAR CORPORATION, HENRY M JACKSON FOUND

Free format text: THE FORMER OWNER WAS: JEFFREY L. STINSON, HING WONG, ALISON D. O'BRIEN, CLARE K. SCHMITT, ANGELA MELTON-CELSA

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired